Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xialiqi Capsule plus tamsulosin versus tamsulosin for benign prostatic hyperplasia
ChiCTR2100050404Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Xialiqi in benign prostatic hyperplasia (BPH) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: International Prostate Symptom Score (IPSS), TCM syndrome score (spleen-kidney qi deficiency with phlegm stasis) and 3 more. Started May 2021; status: recruiting.
02
Drugs
Xialiqi
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2100050404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050404.